Physician profile
Smitha Ajesh
NPI 1356940217
$1,844.76
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.55 · 2022: $837 · 2023: $630 · 2024: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $378.54 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $352.72 | 2022-2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $273.89 | 2022-2024 | Spravato, Invega Sustenna |
| Bausch Health US, LLC | $149.71 | 2021-2023 | Wellbutrin, Aplenzin |
| Sunovion Pharmaceuticals INC. | $112.10 | 2022 | |
| Alkermes, INC. | $104.20 | 2022-2024 | Aristada, Lybalvi |
| Almatica Pharma LLC | $92.73 | 2021-2023 | Sertraline Hcl, Loreev Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.53 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $80.36 | 2022-2023 | Austedo Xr, Uzedy |
| Merck Sharp & Dohme LLC | $74.86 | 2022-2023 | Belsomra |
| Axsome Therapeutics, INC. | $62.52 | 2023 | Auvelity |
| Indivior INC. | $24.40 | 2024 | Perseris |
| Lundbeck LLC | $23.85 | 2022 | |
| Ironshore Pharmaceuticals INC. | $15.73 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smitha Ajesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.